76 related articles for article (PubMed ID: 29039511)
1. TRAIL mutant membrane penetrating peptide alike (TMPPA) TRAIL‑Mu3 enhances the antitumor effects of TRAIL in vitro and in vivo.
Zhu H; Yan J; Xu Q; Wei L; Huang X; Chen S; Yi C
Mol Med Rep; 2017 Dec; 16(6):9607-9612. PubMed ID: 29039511
[TBL] [Abstract][Full Text] [Related]
2. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
3. TRAIL mutant membrane penetrating peptide alike-MuR6-TR enhances the antitumor effects of TRAIL in pancreatic carcinoma both in vitro and in vivo.
Sun L; Chen C; Zhu A; Huang Y; Zhu H; Yi C
Int J Mol Med; 2017 Jun; 39(6):1468-1476. PubMed ID: 28487979
[TBL] [Abstract][Full Text] [Related]
4. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
Zhao L; Dong A; Gu J; Liu Z; Zhang Y; Zhang W; Wang Y; He L; Qian C; Qian Q; Liu X
Cancer Gene Ther; 2006 Nov; 13(11):1011-22. PubMed ID: 16799468
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
Fang F; Wang AP; Yang SF
Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models.
Kopczynski M; Statkiewicz M; Cybulska M; Kuklinska U; Unrug-Bielawska K; Sandowska-Markiewicz Z; Grochowska A; Gajewska M; Kulecka M; Ostrowski J; Mikula M
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808900
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
10. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
11. Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy.
Yoo JD; Bae SM; Seo J; Jeon IS; Vadevoo SMP; Kim SY; Kim IS; Lee B; Kim S
Sci Rep; 2020 Nov; 10(1):19997. PubMed ID: 33203916
[TBL] [Abstract][Full Text] [Related]
12. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo.
Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ
Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246
[TBL] [Abstract][Full Text] [Related]
13. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
14. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
[TBL] [Abstract][Full Text] [Related]
15. Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity.
Yan J; Wang L; Wang Z; Wang Z; Wang B; Zhu R; Bi J; Wu J; Zhang H; Wu H; Yu B; Kong W; Yu X
Cell Death Dis; 2016 Jun; 7(6):e2274. PubMed ID: 27336718
[TBL] [Abstract][Full Text] [Related]
16. Generation of a novel TRAIL mutant by proline to arginine substitution based on codon bias and its antitumor effects.
Zhu A; Wang X; Huang M; Chen C; Yan J; Xu Q; Wei L; Huang X; Zhu H; Yi C
Mol Med Rep; 2017 Oct; 16(4):4973-4979. PubMed ID: 28791342
[TBL] [Abstract][Full Text] [Related]
17. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
[TBL] [Abstract][Full Text] [Related]
18. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
[TBL] [Abstract][Full Text] [Related]
19. A humanized leucine zipper-TRAIL hybrid induces apoptosis of tumors both in vitro and in vivo.
Rozanov D; Spellman P; Savinov A; Strongin AY
PLoS One; 2015; 10(4):e0122980. PubMed ID: 25849628
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway.
Shamimi-Noori S; Yeow WS; Ziauddin MF; Xin H; Tran TL; Xie J; Loehfelm A; Patel P; Yang J; Schrump DS; Fang BL; Nguyen DM
Cancer Gene Ther; 2008 Jun; 15(6):356-70. PubMed ID: 18309355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
